CryoLife E-Vita
(Image from CryoLife)
CryoLife’s E-vita Open NEO hybrid stent graft system, designed to treat aortic arch disease, landed the CE Mark in March.
The hybrid stent graft technologies allow for a one-stage procedure treatment of this condition by combining the surgical arch repair and endovascular descending thoracic repair, according to the company.
The new design features a single tri-branched vessel that enhances ease-of-use and implantation that reduced surgical time, allowing for a potentially safer procedure, according to CEO Pat Mackin.
